Regulatory frameworks for cell therapy products in Japan

Area of Science:

• Biomedical Science
• Regulatory Affairs

Background:

• Japan's regulatory landscape for novel cell therapies is complex.
• Two primary pathways exist for investigating new cell therapy products: clinical trials under the Pharmaceuticals Affairs Act (PAA) and clinical research under the Medical Practitioners Act.

Purpose of the Study:

• To review the regulatory frameworks governing cell therapy products in Japan.
• To elucidate the processes for clinical development and regulatory review of these products.

Main Methods:

• Review of the Pharmaceuticals Affairs Act (PAA) and Medical Practitioners Act.
• Analysis of the requirements for medical product approval within Japan's universal healthcare system.
• Examination of the development and review processes for new drug/device applications.
• Case study of a cell therapy product's clinical review by the Pharmaceuticals and Medical Devices Agency (PMDA).

Main Results:

• Commercialization in Japan requires approval as drugs or medical devices under the PAA.
• Academic researchers developing cell therapies should prioritize clinical trials compliant with the PAA.
• The Pharmaceuticals and Medical Devices Agency (PMDA) plays a key role in the clinical review process.

Conclusions:

• Understanding and adhering to the PAA is crucial for the clinical testing and commercialization of cell therapies in Japan.
• The PAA provides the primary pathway for rigorous clinical evaluation and market approval.
• Successful navigation of the regulatory process, including PMDA review, is essential for bringing innovative cell therapies to patients in Japan.